Author

K. Peters

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Redefining Care for IDH-Mutant Low-Grade Gliomas: Clinical Implications of the INDIGO Trial and Updated Guidelines.

The INDIGO trial compared the IDH inhibitor vorasidenib to a placebo and found the side-effect profile was tolerable compared to that of traditional cytotoxic chemotherapies.

Kristin Bartman, K. Peters · Clinical medicine (London) · 0 citations